• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Advances in immunotherapy for treatment of lung cancer

    2015-12-15 11:38:06JeanBustamanteAlvarezMarGonzlezCaoNikiKarachaliouMariacarmelaSantarpiaSantiagoViteriCristinaTeixidRafaelRosell
    Cancer Biology & Medicine 2015年3期

    Jean G.Bustamante Alvarez, María González-Cao, Niki Karachaliou, Mariacarmela Santarpia, Santiago Viteri,Cristina Teixidó, Rafael Rosell,,5,6

    1Albert Einstein Medical Center, Philadelphia 19141, USA; 2Translational Cancer Research Unit, Instituto Oncológico Dr Rosell,Quirón Dexeus University Hospital, Barcelona 08028, Spain; 3Medical Oncology Unit, Human Pathology Department, University of Messina, Messina 98100, Italy; 4Pangaea Biotech S.L, Barcelona 08028, Spain; 5Cancer Biology & Precision Medicine Program,Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona 08916, Spain; 6Fundación Molecular Oncology Research, Barcelona 08028, Spain

    Introduction

    Efforts in the development of therapy for metastatic lung cancer have led to an evolving arsenal of different approaches including chemotherapy and molecular targeted therapies.However,metastatic lung cancer remains the leading cause of cancer death worldwide and 5-year survival for advanced disease is less than 5%.

    Multiple studies have shown how post-transplant patients undergoing immunosuppressive treatment have increased incidence of different types of cancer, including lymphoproliferative disorders, head and neck and lung cancer,illustrating how immunosuppression is involved in cancer development1,2.By means of different immunosuppressive mechanisms, including “immune check points”, lung cancer manages to evade immunosurveillance.These immune checkpoints are receptors expressed on T cells that regulate the immune response.The first immune checkpoints described were cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the programmed cell death protein 1 (PD-1) and its ligand (PD-L1)3.

    CTLA-4 is expressed on the surface of T-cells and regulates the amplitude of T-cell activation, down-modulates T helper cell activity and enhances regulatory T (Tregs) cell immunosuppressive activity4.PD-1 receptor is an inhibitory molecule present in T activated cells, B cells, monocytes, and natural killer (NK) cells.This receptor binds to its ligand PD-L1(or B7-H1 or CD274) and PD-L2 (or B7 DC or CD273) which are expressed in tumor cells and antigen presenting cells.Up to 57% of non-small cell lung cancers (NSCLCs) express PD-L1 constitutively or as an acquired adaptive mechanism of immune resistance.Expression of tumor PD-L1 protein in NSCLC was associated with increased local lymphocytic infiltration and longer overall survival (OS)5.PD-1 acts within the tumor microenvironment peripherally6, inhibiting T-cell signaling,cytotoxic activity, proliferation, survival and effector function of T cells and also promoting differentiation of CD4+T cells into T regulatory cells and inducing T cell apoptosis6.

    In view of these immunosuppressive mechanisms, clinical research in the last decade has encompassed targeting these immune check points using monoclonal antibodies like ipilimumab, an anti CTLA-4, and pembrolizumab and nivolumab against PD-17,8.These promising monoclonal antibodies were initially approved for metastatic melanoma and now several PD-1/PD-L1 inhibitors have recently been approved by the FDA also for lung cancer.

    Antigen presenting cells present peptides to tumor activated specific T lymphocytes through the major histocompatibility complex class I9,10.Cancer cells also augment secretion of gamma interferon (INF-γ) and tumor necrosis factor α (TNF-α)by CD4+T helper lymphocytes (TH)10.High intratumoral T cell density is required to eliminate cancer cells.Prognosis can be affected by the quantity, localization, and phenotype of infiltrating T cells11; high infiltration by cytotoxic T cells confers good prognosis12.It is also important to consider that some other inhibitory cells infiltrate tumors, like regulatory T CD4+cells FOXP3+(Tregs), cancer associated fibroblasts, myeloid derived suppressor cells and tumor associated macrophages13.These cells generate an immunosuppressive microenvironment by several mechanisms, such as TGF-β and interleukin-10 secretion,secretion of platelet derived growth factor (PDGF) and vascular endothelial growth factor (VEGF).Tumor cells, on the other hand, produce down-regulation of the major histocompatibility complex class I (MHC-I) and antigen expression and increase PD-L1 expression in tissue.As a result, solid tumors attain an immunological response insufficient to eliminate cancer cells,which is the reason why enhancing the function and quantity of CTLs may be of clinical benefit14.

    Inhibitory receptors like CTLA-4, PD-1, TIM3 and LAG3,killer cell immunoglobulin-like receptor (KIR) and VISTA are co-expressed by T cells, secondary to chronic antigen stimulation15-29.This hyporesponsiveness makes cancer behave like a self-protein, inducing immune tolerance by transforming T-cell into an “exhaustion phenotype”30-32.

    PD-1 receptor is expressed by activated T cells, NK cells,monocytes and B cells and binds PD-L1 (B7-H1 or CD274)and PD-L2 (B7-DC or CD273).PD-L1 is present in malignant cells as well as antigen presenter cells, myeloid cells, epithelial and lymphoid cells, and represents a constitutive or acquired mechanism of immune resistance33.PD-1/PD-L1 inhibit cytotoxic T lymphocyte proliferation, survival and effector activity, induce apoptosis of infiltrative T cells and increase the amount of regulatory T cells in the tumor microenvironment34.

    Clinical development of anti PD-1 and PDL1 inhibitors in NSCLC

    Currently, there are three PD-1/PD-L1 inhibitors available for lung cancer: nivolumab for squamous NSCLC (approved by FDA March 2015), pembrolizumab for the treatment of NSCLC and MPDL3280A from Roche (both granted breakthrough therapy designation) for NSCLC that has progressed on prior treatment (platinum based chemotherapy or targeted therapy for EGFR or ALK positive patients).

    NSCLC was found to express PD-L1 in 27% to 57% of cases either in the cellular membrane or the cytoplasm35,36.PD-L1 and other molecules that act as immune checkpoints are upregulated in response to substances secreted by lung tumor cells,such as the enzyme IDO which also down-regulates MHC-137.Other immunosuppressive factors like IL-10 and TGF-β are secreted by tumor cells, editing the tumor microenvironment to attenuate immune response38.There are several clinical trials ongoing in lung cancer with different immune checkpoints blockers (Tables 1,2).

    Anti PD-1 drugs

    Nivolumab is a fully humanized anti-PD-1 monoclonal antibody from Bristol Meyer Squibb (BMS).A phase I trial in 2012 in previously treated NSCLC patients treated with intravenous nivolumab every 2 weeks for 12 cycles at different doses (0.1 to 10.0 mg per kilogram of body weight) demonstrated an overall response rate (ORR) of 18% by RECIST 1.1 criteria.These responses were seen in non-squamous as well as squamous NSCLC (ORR of 12% and 33%, respectively)7.Long term follow-up of the phase I trial with nivolumab in 129 previously treated NSCLC patients showed that in 50% of patients who responded, response was already evident by week 8 after starting treatment.In this trial, the ORR was 14% up to 25% and OS was 18% at 3 years.The median duration of response was 17 months.Pneumonitis was observed in 7% of patients, and grade 3-4 toxicities in 14%.The most common side effects were fatigue, diarrhea, and anorexia63.

    The phase III CheckMate 017 trial reported an OS advantagefor nivolumab in pretreated squamous NSCLC.It included 272 squamous NSCLC patients regardless of PD-L1 status.Patients were randomized to nivolumab (3 mg/kg i.v.in 60 min every 2 weeks) versus docetaxel.The OS endpoint was met early and the study was therefore stopped in January 2015.Median OS was 9.2 months in the nivolumab arm (95% CI: 7.3-13.3) and 6.2 months in the docetaxel arm (95% CI: 5.1-7.3).At 1-year,the OS was 42% for the nivolumab group versus 24% in the docetaxel group.The hazard ratio (HR) was 0.59 (95% CI: 0.44-0.79; P=0.00025).Nivolumab also improved median progression free survival (PFS) 3.5 vs.2.8 months with docetaxel (HR =0.62;95% CI: 0.47-0.81; P=0.0004) (Table 1)47.

    Table 1 Results of trials with PD-1 and PD-L1 inhibitors

    CheckMate 063 assessed safety profile of nivolumab in squamous NSCLC.This was a phase II open label, multinational and multicenter single arm trial in 117 patients.Nivolumab was given to squamous NSCLC patients who had progressed to platinum based therapy and second line systemic chemotherapy.As with CheckMate 017, this trial included patients regardless of PD-L1 status.The most common adverse reactions were fatigue (50%), dyspnea (38%), musculoskeletal pain (36%),decreased appetite (35%), cough (32%), nausea (29%), and constipation (24%).There were two treatment-associated deaths caused by pneumonia and ischemic stroke that occurred in patients with multiple comorbidities and progressive disease.In 27% of patients, nivolumab was stopped due to severe adverse reactions.Seventeen out of 117 patients (ORR: 15%; 95% CI:9-22) had partial responses with durability ranging from 1.9 to 11.5 months; 59% had responses of 6 months or longer42.

    Table 2 Current trials on anti PD-1 and anti PD-L1 inhibitors

    Table 2 Current trials on anti PD-1 and anti PD-L1 inhibitors

    A phase III trial (CheckMate 057) randomized 582 patients with advanced non-squamous NSCLC after failing platinum doublet chemotherapy to nivolumab at 3 mg/kg i.v.every 2 weeks (n=292) or docetaxel (n=290).The study was stopped early after the primary endpoint of improved OS was reached.Median OS was 12.2 months with nivolumab vs.9.4 months with docetaxel (HR =0.73; 95% CI: 0.59-0.89; P=0.00155),with a 1-year OS of 50.5% vs.39.0% for docetaxel.ORR was 19%vs.12% (P=0.0246).Fifty-two percent of the PD-1 inhibitor responses are still ongoing compared with 14% of the docetaxel responses48(Table 1).

    Results from a phase III trial CheckMate 026 comparing nivolumab versus chemotherapy in the first line setting for PDL1 positive NSCLC patients are pending (NCT02041533).

    There is also an ongoing phase I trial with multiple arms using combinations of nivolumab with chemotherapy, bevacizumab,ipilimumab or erlotinib (CheckMate 012, NCT01454102).

    Now a phase III trial is planned to test the combination of nivolumab plus ipilimumab vs.chemotherapy in the first line setting (CheckMate 227, NCT02477826).

    In small cell lung cancer (SCLC) a phase III trial will test nivolumab vs.topotecan in the second line setting (CheckMate 331, NCT02481830).

    Preliminary results of platinum doublets combined with nivolumab have showed similar response rates when compared to chemotherapy alone in the first line setting (ORR: 33%-47%)and OS rate was 86 % at 18 months in the nivolumab combined with carboplatin and taxol arm49.

    Pembrolizumab (MK-3475) is an anti PD-1 monoclonal antibody from Merck Sharp & Dohme laboratory.Data from a phase Ib trial in previously treated patients showed an ORR of 21% by RECIST1.1 (26% in treatment na?ve and 20% in previously treated patients).In treatment na?ve patients, median PFS was 27 weeks, and median overall survival was not reached(OS at 6 months was 86%).In previously treated patients,median PFS was 10 weeks and OS 8.2 months.In the pooled population, median PFS was 13 weeks and 6-month PFS rate was 30%; median OS was 8.2 months with a 6-month OS rate of 64%.The drug was well tolerated with grade 2-4 adverse events in 10% of cases, most commonly pneumonitis54,64.In view of these results, pembrolizumab (formerly known as lambrolizumab) was designated as breakthrough therapy for lung cancer treatment by the FDA.

    Currently pembrolizumab is being compared with docetaxel in a phase II/III trial in advanced PD-L1 positive NSCLC(NCT01905657).Pembrolizumab is administered every 3 weeks at two different doses (2 mg/kg i.v.every 3 weeks and 10 mg/kg i.v.every 3 weeks) vs.docetaxel (75 mg/m i.v.every 3 weeks).

    A phase I trial in PD-L1 positive NSCLC with pembrolizumab(NCT02039674) is currently ongoing, as is a phase I/II trial with ipilimumab or chemotherapy in combination with pembrolizumab (NCT02039674) and a phase II trial of adjuvant pembrolizumab after chemo-radiotherapy for stage III NSCLC patients (NCT02343952) (Table 2).

    In addition to the above mentioned trials, two phase III trials of pembrolizumab at a fixed dose of 200 mg i.v.every 3 weeks for up to 35 treatments is also being compared in the first line setting vs.platinum based chemotherapy in PD-L1 positive and PD-L1 strong positive NSCLC patients (Keynote 042, NCT02220894 and Keynote 024, NCT02142738) (Table 2).

    Data in SCLC patients were presented in May 2015 as preliminary results of an ongoing multi-cohort, phase Ib study of pembrolizumab in patients with PD-L1+ advanced solid tumors(Keynote 028).The SCLC cohort had an ORR of 35% with durable responses56(Table 1).

    An ongoing phase II trial is testing pembrolizumab in patients with extensive stage small cell lung cancer after completion of combination chemotherapy (NCT02359019) (Table 2).

    Anti PD-L1 drugs

    BMS-936559 is a fully humanized IgG4 monoclonal antibody against PD-L1.This anti PD-L1 was used in 207 patients with advanced stage solid tumors, 75 of whom had NSCLC.The results of the study showed an ORR close to 10% and stable disease for up to 6 months in 18% patients58.However, further development of this drug has been halted by Brystol Meyer Squibb (Table 1).

    MEDI4736 (Astra Zeneca) is a monoclonal antibody designed with a mutated FC domain in order to prevent antibody-dependent cell mediated cytotoxicity (ADCC).Preliminary results of a phase I trial in patients with different solid tumor types including NSCLC reported clinical benefit and durable disease control with no dose limiting toxicities or grade 3-4 toxicities60.Objective response was seen in 23% of patients with pretreated NSCLC (12 out of 53 evaluable patients) in the phase II trial60.Results reported at the 2014 ASCO annual meeting showed the drug was well tolerated at all tested doses.Doses were escalated from 0.1 to 10 mg/kg every 2 weeks,with extension to 15 mg/kg every 3 weeks65.Pneumonitis,hyperglycemia and colitis were not reported.

    Preliminary results from an ongoing study with 346 patients with solid tumors, of whom 143 had NSCLC, used MEDI4736 at dosages of 10 mg/kg every 2 weeks for 1 year.Only 6% of patients had grade 3-4 drug related serious adverse events.The median treatment duration was 8 weeks, and activity was seen as early as 6 weeks.After finishing active therapy, ORR in NSCLC was 13%59.

    Adjuvant MEDI4736 after chemo-radiotherapy for unresectable stage III NSCLC is currently being tested in a phase III trial (10 mg/kg i.v.every 2 weeks) (NCT02125461).Safety of doses of 0.1-10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks is also been evaluated in a phase I trial in advanced solid tumors including NSCLC (NCT01693562).The anti CTLA-4 IgG2 monoclonal antibody tremelimumab is also being tested in combination with MEDI4736 in a phase Ib trial in NSCLC.(NCT02000947), and a phase III trial in the first line setting will compare the combination with tremelimumab vs.MEDI4736 as single agent vs.chemotherapy in advanced NSCLC according to PD-L1 status (Table 2).

    For EGFR positive patients with T790 mutation, a phase III trial is comparing AZD9291 as single agent vs.combination with MEDI4736 (NCT02143466).Other ongoing phase I trials are combining small molecules with MEDI4736 (NCT02179671,NCT02143466).There is currently a phase II trial recruiting PD-L1 positive patients who have received at least two prior systemic treatment regimens including one platinum-based chemotherapy regimen to receive MEDI4736 (NCT02087423)(Table 2).

    Atezolizumab MPDL3280A from Hoffman la Roche is also an anti-PD-L1 monoclonal antibody, IgG type with Fc domain engineered modification to avoid ADCC.Preliminary phase I results in previously treated advanced NSCLC patients reported a response rate of 23% in squamous and non-squamous NSCLC,24-week PFS was 48% and median time to response was 12 weeks61,66.Results from the phase II POPLAR study presented at the 2015 ASCO annual meeting showed that atezolizumab improved median OS compared with docetaxel in previously treated patients with PD-L1 strong positive NSCLC.For the 47 patients with high PD-L1 expression from 277 included in the study, median OS was not reached in those treated with atezolizumab vs.11 months in patients treated with docetaxel (HR =0.46; 95% CI: 0.19-1.09).In high expression PD-L1 patients, ORR was 38% with atezolizumab vs.13% with chemotherapy62(Table 1).

    The FIR trial is completed and results are pending.This is a phase II study using this drug in the first setting of PD-L1 positive NSCLC patients (NCT01846416).Other ongoing trials are a phase I study assessing the combination of erlotinib and MPDL3280A in EGFR mutated adenocarcinoma(NCT02013219), a phase III trial where MPDL3280A is being tested at a dose of 1,200 mg i.v.every 3 weeks vs.docetaxel at dose of 75 mg/m2i.v.every 3 weeks after chemotherapy failure(NCT02008227), a phase III trial in the first line setting in nonsquamous NSCLC (NCT02409355) and three phase III trials testing the combination of MPDL3280A in the first line setting of non-squamous NSCLC (NCT022367781, NCT02409342,NCT02367794).

    Anti CTLA-4 antibodies

    Ipilimumab (anti CTL-4 antibody) is a fully humanized Ig G1 monoclonal antibody approved for metastatic melanoma.It was tested in a phase II trial in 334 lung cancer patients (204 NSCLC and 104 SCLC patients) in the first line setting.The trial featured two ipilimumab arms in combination with chemotherapy(paclitaxel plus carboplatin), one arm in a phased schedule and the other one in concomitant schedule vs.a third arm of chemotherapy alone.Median PFS was longer with the phased combination (5.1 vs.42 months; HR =0.69; 95% CI: 0.48-1.00;P=0.02).Subgroup analysis showed higher activity in squamous cell lung cancer.Toxicity was moderate with grade 3-4 toxic effects in 15% of patients39.A phase III trial with ipilimumab in combination with chemotherapy in a phased schedule in squamous NSCLC was completed and results are pending(NCT01285609).Ipilimumab is also being tested in SCLC(NCT01331525, NCT01450761, and NCT02046733) and in combination with ALK and EGFR inhibitors (NCT01998126).

    Tremelimumab is a monoclonal antibody similar to ipilimumab and is developed simultaneously.Although tremelimumab is similar to ipilimumab, the pivotal trail in advanced melanoma was negative, and this was the reason why clinical development of the drug was stopped during years.Tremelimumab was also tested in NSCLC in a phase II study including pre-treated patients.Patients were randomized to tremelimumab or best supportive care after four cycles of a platinum combination.The response rate was poor,just 5%, and there were no differences in PFS41.

    This drug is now being tested in combination with the target drug gefitinib (NCT02040064), with the anti PD-L1 MEDI4736 (NCT02000947, NCT02179671) and with the OX-40 agonist MEDI6469 (NCT02205333) (Table 2).

    PD-L1 immunohistochemical expression and response to therapy

    Immunohistochemistry (IHC) has been used to measure PDL1 expression in cancer cells, as well as in tumor infiltrating lymphocytes67.Interpretation of outcomes is complicated due to the range of techniques and because there are different antibodies used by every pharmaceutical company.Also, timing of the biopsy is a variable that can affect results since expression of the PD-L1 changes during tumor evolution68,69.The cut-off at which PDL1 positivity is considered positive, is an important factor for the interpretation of results.For example, 1% of cut-off has been used in studies with pembrolizumab and depending on this percentage,negativity, light positivity or intense positivity has been defined.Taking into account these different cut-off values, there is a reported 30% of intense positivity of PD-L1 for NSCLC.In the reported studies with nivolumab, a 5% of membrane staining of tumor cells was considered as positive.About 33%-48% of tumor samples were PD-L1 positive in the nivolumab studies.In the studies of MPDL3280A, PD-L1 positivity criteria included 5% of IHC staining on tumor infiltrating lymphocytes and tumor cells.According to these criteria, 25% of NSCLC samples were positive for PD-L1 expression66.

    Further studies are required to demonstrate if PD-L1 expression by IHC correlates with a higher response rate when tumor cells are positive for staining.Median response rate of 38% in PD-L1 positive patients (ranging from 23% to 83%) vs.7%(ranging from 0%-15%) in PD-L1 negative patients have been

    A pembrolizumab trial, Keynote 001, has shown improved ORR in patients with positivity for PD-L1 expression.A total of 495 patients were assigned to receive pembrolizumab(at a dose of either 2 or 10 mg per kilogram of body weight every 3 weeks or 10 mg per kilogram every 2 weeks) to either a training group (182 patients) or a validation group (313 patients).Results of PD-L1 expression were reported as the percentage of neoplastic cells with PD-L1 membrane staining;objective responses among all patients was 19.4%, and the median duration of response was 12.5 months.The median PFS was 3.7 months, and median OS was 12.0 months.Cutoff for the training group was PD-L1 expression in at least 50% of tumor cells.A response rate of 45.2% was seen among patients with a proportion score of at least 50% in the validation group, and, among patients with a proportion score of at least 50%; median PFS was 6.3 months while median OS was not reached68,72.Other studies as the study from Garon et al.72reported higher response rate and longer survival for PD-L1 positive cases.

    In other types of tumors like melanoma, the predictive value of PD-L1 can be different, as the response rate in PDL1 negative cases is higher than in PD-L1 negative lung cancer cases73.In melanoma, PD-L1 expression, as well as the presence of infiltrating CD8 lymphocytes, has been described as a better predictive factor for response to anti PD-1 drugs than considering only the PD-L1 expression74.

    Synergistic combinations and innovative approaches

    Synergy can be achieved by targeting different immune checkpoints with combinations, as combining antibodies anti checkpoints with target drugs, antiangiogenic drugs or chemotherapy.

    After promising activity in melanoma was reported, trials in lung cancer demonstrated that the combination of a PD-1 inhibitor and anti CTLA-4 antibody was active, with an ORR of 13%-20%52.Several ongoing trials are testing different combinations in lung cancer, including several phase III trials (Table 2).

    In a phase I/II clinical trial (CheckMate 032), nivolumab was studied with or without ipilimumab for treatment of recurrent SCLC.This open-label study randomized patients to nivolumab 3 mg/kg i.v.every 2 weeks or nivolumab plus ipilimumab (1+1,1+3 or 3+1 mg/kg) i.v.every 3 weeks for four cycles, followed by nivolumab 3 mg/kg every 2 weeks.ORR was 18% with nivolumab and 17% with nivolumab/ipilimumab.Median OS was 4.4 months with nivolumab monotherapy and 8.2 months with combination therapy53(Table 1).

    Interim results from a phase I study evaluating pembrolizumab plus ipilimumab in patients with recurrent NSCLC reported an ORR of 71%, showing a decrease in target lesion burden57(Table 1).

    Another possible combination is MAPK pathway inhibitors.In the past two decades, targeted therapies in NSCLC, mainly EGFR inhibitors such as erlotinib, gefitinib, afatinib and ALK and ROS-1 inhibitors like crizotinib, have developed rapidly and have shown high response rates75.The possible combinations with immunotherapy could presumably allow long lasting effects by means of enhanced tumor antigen presentation by dendritic cells after apoptosis, necrosis and immune checkpoint blockade,allowing infiltrating cytotoxic T cells to attack tumor cells76.

    Akbay et al.77showed that in murine lung tumor cells there is upregulation of tumor PD-L1 via mutant EGFR signaling,and that in preclinical models there was a survival benefit when therapeutic blockade of the PD-L1 pathway was attempted.

    A study analyzing biopsies from 123 NSCLC patients reported 56 EGFR mutant and 29 KRAS mutant tumors,with a significant correlation of EGFR mutation with PDL1 expression, and KRAS mutation with PD-1 expression.Moreover, EGFR positive patients treated with EGFR inhibitors had better survival when they had PD-L1 molecule expression.In a phase I trial, erlotinib plus nivolumab showed a median PFS of 29 months, an OS rate of 64% at 18 months and ORR of 15%78.

    Trials testing the combination of erlotinib, gefitinib, afatinib or novel anti EGFR drugs plus ipilimumab, nivolumab,MPDL3280A and tremelimumab are currently ongoing.Also a phase I trial is ongoing testing the combination for ALK positive of ceritinib and nivolumab tumors (NCT02393625) (Table 2).

    Several trials are currently assessing different aspects of the combination of antiangiogenic and immunotherapy, including a phase I trial evaluating the safety and tolerability of nivolumab as maintenance therapy in combination with bevacizumab in NSCLC (NCT01454102) (Table 2).

    With regard to combinations with chemotherapy, ipilimumab was studied in a phase III trial with dacarbazine for advanced melanoma.OS was significantly longer in the arm receiving ipilimumab plus dacarbazine than in the group receiving dacarbazine plus placebo (11.2 vs.9.1 months; HR for death=0.72; P<0.001)79.Ipilimumab is currently being studied in combination with lenalidomide for advanced or metastatic cancers with no available standard therapy (NCT01750983).As we have previously mentioned, ipilimumab was studied in a phase II trial in chemotherapy na?ve patients with NSCLC.Patients were randomly assigned to receive paclitaxel and carboplatin with either placebo or concurrent ipilimumab or phased ipilimumab.The study met its primary end point of improvement in terms of immune-related progression-free survival (irPFS) for phased ipilimumab vs.the control (HR =0.72; P=0.05), but not for the concurrent arm (HR =0.81; P=0.13)39.Nivolumab has also been studied in a phase I trial in combination with carboplatin and nab-paclitaxel in stage IIIB and IV NSCLC (NCT02309177).There is also a phase I multi-arm study of nivolumab in combination with gemcitabine/cisplatin, pemetrexed/cisplatin,carboplatin/paclitaxel, bevacizumab maintenance, erlotinib,ipilimumab or as monotherapy in subjects with stage IIIB/IV NSCLC (NCT02309177) (Table 2).

    Radiation therapy has been described to induce tumor regression in non-irradiated sites, and this rare phenomenon is called the “abscopal effect”.There was a case of a melanoma patient treated with ipilimumab and radiotherapy; the patient had a systemic response to localized radiotherapy after progressing on ipilimumab.Non-irradiated areas also regressed and disease remained stable and minimal months later80.Radiotherapy has been shown to enhance antigen presentation by myeloid cells within the tumor microenvironment, therefore increasing T-cell killing of the malignant cells, a mechanism which is thought to mediate the abscopal effect.Combinations of radiotherapy with immune checkpoint inhibitors are currently being studied.For example, there is an ongoing phase II trial of ipilimumab with stereotactic body irradiation in advanced lung cancer (NCT02239900), pembrolizumab with hypofractionated stereotactic radiation therapy (NCT02444741), and pembrolizumab with concurrent chemo-radiation for SCLC(NCT02402920).

    Toxicity

    When combining ipilimumab with PD-1 inhibitors like nivolumab in melanoma, drug-related adverse events of grade 3 or 4 were reported in 53% of patients compared with 18% of patients who received ipilimumab monotherapy72,81,82.Grade 3 or 4 adverse events, regardless of attribution, were observed in 72%of patients, and grade 3 or 4 treatment-related events were noted in 53%, with the most common events being elevated levels of lipase (in 13% of patients), aspartate aminotransferase (in 13%),and alanine aminotransferase (in 11%).A total of 6 in 28 patients(21%) had grade 3 or 4 treatment-related events that were doselimiting.

    Even though ipilimumab is generally well tolerated,severe immune mediated side effects have been observed including enterocolitis, hepatitis, dermatitis, neuropathies, and endocrinopathies.These reactions can manifest during treatment or even months after discontinuation of ipilimumab.In the phase III study of ipilimumab, enterocolitis was the most common severe toxicity, seen in 34 of 511 patients.One percent of patients had bowel perforation and 0.8% died83,84.Treatment of severe reactions mainly consists of discontinuation of ipilimumab and initiation of systemic corticosteroids at a dosage of 1 to 2 mg/kg per day of prednisone or equivalent with taper over a period of 1 month once the toxicities have considerably improved85.

    Nivolumab is a better tolerated drug.The most common adverse reactions (≥20%) reported in a phase III clinical trial were fatigue (50%), dyspnea (38%), musculoskeletal pain (36%),decreased appetite (35%), cough (32%), nausea (29%), and constipation (24%).Only 6% of grade 3 or 4 toxicities are seen.Skin toxicity, including rash, pruritus, and vitiligo are the most commonly seen reactions (31% of the cases).Diarrhea was seen in 11% of cases and pneumonitis in 3%.Transaminitis was seen in 11% and thyroid abnormalities in 3%.Treatment of severe reactions consists of withdrawal of the drug and, if required,prednisone 1 to 2 mg/kg daily should be given until the patient is back at baseline and then tapered over a month86.

    With pembrolizumab, 13% of patients experienced grade 3 or 4 drug-related adverse events.Common low grade reactions were fatigue, asthenia, fever, chills, myalgias and headaches.Pneumonitis was reported in 4% of cases and grade 3 transaminitis.Toxicities improved after pembrolizumab discontinuation and corticosteroid therapy.Only one case of grade 3 diarrhea was reported, which improved without steroids,and 8% of hypothyroidism which improved with thyroid hormone replacement72.

    Other immunomodulatory and agonistic molecules

    Other immune checkpoint antibodies are currently been studied as single agents, and more interestingly, in combination with other checkpoint inhibitors.The most relevant immune checkpoints currently under clinical investigation are lymphocyte activation gene -3 (LAG-3), KIR, OX 40, GITR,and 4-1BB.

    As for LAG-3, preclinical studies have shown co-expression of LAG-3 and PD-1 on tumor infiltrating cells.Combinations of anti-LAG-3 antibodies with anti PD-1 antibodies showed decreased tumor growth and enhanced antitumor immunity,and also maintained immune homeostasis with decreased autoimmune responses87.There is currently an ongoing phase I trial testing anti-LAG-3 in advanced NSCLC (NCT01968109).

    KIR is a molecule in the NK cell that binds HLA molecules to the surface of tumoral cells, inhibiting NK lymphocyte cytotoxic activity against malignant cells.If KIR is blocked, then NK cells are unblinded and can recognize and attack tumoral cells88.Lirilumab is an anti-KIR antibody currently in phase I trials in NSCLC (NCT01750580).

    GITR affects regulatory T cells (Tregs) and also acts as a costimulatory receptor expressed after T cell activation that enhances T cell function and survival.Treatment with GITR agonistic antibody destabilizes intra-tumor Tregs allowing for more efficient cytolysis by CD8+T cells89.A phase I trial with anti-GITR antibody TRX-518 is ongoing in advanced solid tumors (NCT01239134).

    4-1BB, also known as CD137 receptor, a member of the TNF family of receptors, is an immunomodulatory molecule expressed in immune cells.Urelumab (BMS 663513) is a CD137 agonist that has been tested in a phase I/II study with promising activity, although marked hepatic toxicities have been reported.A study of urelumab in combination with chemoradiotherapy for NSCLC has been terminated (NCT00461110)and the combination with nivolumab is being tested in solid tumors and B cell non-Hodgkin lymphoma (NCT02253992)90.There is an ongoing trial with 4-1BB agonist PF-05082566 plus PD-1 inhibitor MK-3475 in patients with solid tumors(NCT02179918)90.

    OX40 promotes T cell survival and expansion.Preclinical studies showed that OX40 agonists increase anti-tumor immunity and improve disease free survival.Patients treated with one course of the antiOX40 mAb showed regression of at least one metastatic lesion in 12/30 patients and an acceptable toxicity profile91.

    Cancer vaccines

    Two types of vaccines, antigen specific and cell-based, are currently being studied in lung cancer.

    Antigen specific vaccines

    Several vaccines target tumor specific antigens, as those against melanoma-associated antigen-A3 (MAGE-3), MUC-1, EGFR,human telomerase reverse transcriptase (hTERT) or NYESO-1.

    MAGE-A3: 35%-42% of NSCLCs have expression of MAGE-A3, which is presented to T cells.A phase II trial showed a correlation between the expression of a gene signature and immune related transcripts associated with better outcome when a MAGE A3 vaccine was used in NSCLC92.

    L-BLP25 (stimuvax) targets the peptide MUC1 which is overexpressed in lung cancer and associated with poor prognosis93.Early trials with L-BLP25 were promising but the phase III trial did not meet its primary endpoint of OS94.Two studies are currently ongoing to evaluate L-BLP25, one in combination with bevacizumab for inoperable patients with stage III-IV NSCLC following chemo/radiotherapy(NCT00828009), and another in Asian patients is pending results (NCT01015443).

    rEGF: 40%-80% of NSCLCs express EGFR.Therefore a vaccine composed of humanized recombinant EGF is being studied.Two trials were started but terminated to initiate a new phase III with a biomarker to enrich the population.Median OS was 11.7 months for patients with anti-EGF antibody response vs.3.6 months for non-responders95.A phase III trial is now planned (NCT01444118).

    Anti-telomerase-based vaccine GV1001 showed clinical benefit in a phase I and II trial, with PFS improvement in inoperable NSCLC after chemoradiation (19 months in responders vs.3.5 months in non-responders, P=0.001).Responders were those who developed GV1001-specific T cell memory responses and had IFN-γ (high)/IL-10(low)/IL-4(low)cytokine profiles96.

    An NY-ESO-1 vaccine achieved antibody responses in 9 of 10 patients.Of these 10, 2 patients with lung cancer and 1 with esophageal cancer showed stable disease97.A clinical trial in cancer patients with tumors expressing NY-ESO-1 tested the vaccine with or without sirolimus (NCT01522820).

    Cell based vaccines

    Belagenpumatucel-L (Lucanix) is composed of five transforming growth factor B2 (TGF-B2) antisense gene-modified allogenic NSCLC cell lines.In a phase III clinical trial for those patients that were included after completing 12 weeks of chemotherapy,survival analysis showed improvement in overall survival (20.7 vs.13.4 months, P=0.8) and for those patients treated with radiotherapy, median survival was 40 vs.10 months (P=0.036)98.

    Tergenpumatucel-L consists of genetically modified allogeneic NSCLC tumor cells lines with the alpha-(1,3)-galactosyltransferase (αGal) moiety on the cell surfaces which generates an innate immune reaction, killing the foreign NSCLC tumor cells.In a phase II clinical trial, 28 patients with metastatic NSCLC or recurrent disease received the vaccine with a median OS of 11.3 months and a long stabilization in 8 of 28 patients with one patient alive after 50 months of follow-up.Patients who received salvage chemotherapy after progressing on tergenpumatucel-L had a better OR to subsequent chemotherapy treatments than patients who had not received prior tergenpumatucel-L99.

    Peptide vaccines have been also tested in solid tumors, such as the peptide vaccine against the indoleamine 2,3-dioxygenase(IDO) enzyme.In a phase I trial in 15 advanced NSCLC,HLA-A2 positive patients, one patient developed a partial response after 1 year of treatment with the vaccine, and longlasting stable disease was demonstrated in further six patients.Median OS was 25.9 months.Furthermore, expression of IDO was detected in nine of ten tumor biopsies by IHC.In longterm analyses of two clinically responding patients, the ratio of kynurenine/tryptophan in serum (Kyn/Trp) remained stable100.

    Conclusion

    New strategies to treat lung cancer, inducing durable responses to therapy, are currently being developed.The incorporation of immunotherapy to the arsenal of drugs for treatment of lung cancer is a promising approach to reach these goals, with low rates of side effects.

    Personalized medicine currently offers the best profile in terms of side effects and efficacy in different cancers, and combination with immune checkpoint blockers could enhance its activity.

    In view of promising results reported, now the challenge is finding those biomarkers that can help us select the best treatment approach for every patient.

    Conflict of interest statement

    No potential conflicts of interest are disclosed.

    1.Finn OJ.Cancer immunology.N Engl J Med 2008;358:2704-2715.

    2.Roithmaier S, Haydon AM, Loi S, Esmore D, Griffiths A, Bergin P, et al.Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience.J Heart Lung Transplant 2007;26:845-849.

    3.Anagnostou VK, Brahmer JR.Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.Clin Cancer Res 2015;21:976-984.

    4.Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al.Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.Nat Med 2002;8:793-800.

    5.Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, et al.Programmed death ligand-1 expression in nonsmall cell lung cancer.Lab Invest 2014;94:107-116.

    6.Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ.Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.Immunity 2007;27:111-122.

    7.Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC,McDermott DF, et al.Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med 2012;366:2443-2454.

    8.Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al.Phase I study of single-agent anti-programmed death-1(MDX-1106) in refractory solid tumors: safety, clinical activity,pharmacodynamics, and immunologic correlates.J Clin Oncol 2010;28:3167-3175.

    9.Lenschow DJ, Walunas TL, Bluestone JA.CD28/B7 system of T cell costimulation.Annu Rev Immunol 1996;14:233-258.

    10.Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, et al.Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.Cell 1992;71:1093-1102.

    11.Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, et al.Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.J Clin Oncol 2010;28:105-113.

    12.Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al.Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in nodepositive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.J Clin Oncol 2013;31:860-867.

    13.Fridman WH, Pages F, Sautes-Fridman C, Galon J.The immune contexture in human tumours: impact on clinical outcome.Nat Rev Cancer 2012;12:298-306.

    14.Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al.Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.N Engl J Med 2003;348:203-213.

    15.Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK,Ledbetter JA.CTLA-4 is a second receptor for the B cell activation antigen B7.J Exp Med 1991;174:561-569.

    16. Thompson CB, Allison JP.The emerging role of CTLA-4 as an immune attenuator.Immunity 1997;7:445-450.

    17.Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ,Green JM, et al.CTLA-4 can function as a negative regulator of T cell activation.Immunity 1994;1:405-413.

    18.Kearney ER, Walunas TL, Karr RW, Morton PA, Loh DY,Bluestone JA, et al.Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4.J Immunol 1995;155:1032-1036.

    19.Krummel MF, Allison JP.CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.J Exp Med 1995;182:459-465.

    20.Krummel MF, Sullivan TJ, Allison JP.Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo.Int Immunol 1996;8:519-523.

    21.Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA,Sharpe AH.Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.Immunity 1995;3:541-547.

    22.Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al.Role of LAG-3 in regulatory T cells.Immunity 2004;21:503-513.

    23.Gandhi MK, Lambley E, Duraiswamy J, Dua U, Smith C, ElliottS, et al.Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigenspecific CD8+ T-cell function in Hodgkin lymphoma patients.Blood 2006;108:2280-2289.

    24.Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ,et al.The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity.Nat Immunol 2005;6:1245-1252.

    25.Sabatos CA, Chakravarti S, Cha E, Schubart A, Sanchez-Fueyo A,Zheng XX, et al.Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance.Nat Immunol 2003;4:1102-1110.

    26.Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, et al.TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression.PLoS One 2012;7:e30676.

    27.Zhuang X, Zhang X, Xia X, Zhang C, Liang X, Gao L, et al.Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC.Am J Clin Pathol 2012;137:978-985.

    28.Zhou P, Shaffer DR, Alvarez Arias DA, Nakazaki Y, Pos W, Torres AJ, et al.In vivo discovery of immunotherapy targets in the tumour microenvironment.Nature 2014;506:52-57.

    29.Le Mercier I, Chen W, Lines JL, Day M, Li J, Sergent P, et al.VISTA regulates the development of protective antitumor immunity.Cancer Res 2014;74:1933-1944.

    30.Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A,Lee KP, et al.Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.Science 1995;270:985-988.

    31.Chambers CA, Sullivan TJ, Allison JP.Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells.Immunity 1997;7:885-895.

    32.Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK,Anderson AC.Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.J Exp Med 2010;207:2187-2194.

    33.Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy.Nat Rev Cancer 2012;12:252-264.

    34.Karwacz K, Bricogne C, MacDonald D, Arce F, Bennett CL,Collins M, et al.PD-L1 co-stimulation contributes to ligandinduced T cell receptor down-modulation on CD8+ T cells.EMBO Mol Med 2011;3:581-592.

    35.Chen YB, Mu CY, Huang JA.Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study.Tumori 2012;98:751-755.

    36.Chen YY, Wang LB, Zhu HL, Li XY, Zhu YP, Yin YL, et al.Relationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patients.Chin Med Sci J 2013;28:147-151.

    37.Lee SY, Choi HK, Lee KJ, Jung JY, Hur GY, Jung KH, et al.The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.J Immunother 2009;32:22-28.

    38.Srivastava MK, Andersson A, Zhu L, Harris-White M, Lee JM, Dubinett S, et al.Myeloid suppressor cells and immune modulation in lung cancer.Immunotherapy 2012;4:291-304.

    39.Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al.Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer:results from a randomized, double-blind, multicenter phase II study.J Clin Oncol 2012;30:2046-2054.

    40.Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R,et al.Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.Ann Oncol 2013;24:75-83.

    41.Zatloukal P, Heo SD, Park K, Kang J, Butts C, Bradford D, et al.Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC).J Clin Oncol 2009;27:abstr 8071.

    42.Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK,Antonia SJ, et al.Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced,refractory squamous non-small-cell lung cancer (CheckMate 063):a phase 2, single-arm trial.Lancet Oncol 2015;16:257-265.

    43.Ramalingam SS, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al.Phase II study of nivolumab (anti-PD-1,BMS-936558, ONO-4538) in patients with advanced, refractory squamous non-small cell lung cancer: metastatic non-small cell lung cancer.Int J Radiat Oncol Biol Phys 2014;90:1266-1267.

    44.Rizvi NA, Shepherd FA, Antonia SJ, Bahmer JR, Chow LQ,Goldman J, et al.First-line monotherapy with nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in advanced non-small cell lung cancer (NSCLC): safety, efficacy, and correlation of outcomes with PD-L1 status.Int J Radiat Oncol Biol Phys 2014;90:S31.

    45.Brahmer JR, Horn L, Antonia SJ, Gandhi L, Sequist LV, Sankar V, et al.Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients(pts) with previously treated advanced non-small cell lung cancer(NSCLC).J Clin Oncol 2013;31:abstr 8030.

    46.Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA,et al.Long-term survival, clinical activity, and safety of nivolumab(Anti-PD-1; BMS-936558, ONO-4538) in patients (Pts) with advanced non-small cell lung cancer (NSCLC).Int J Radiat Oncol Biol Phys 2014;90:S34.

    47.Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE,Poddubskaya E, et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.N Engl J Med 2015;373:123-135.

    48.Paz-Ares L, Horn L, Borghaei H, Spigel DR, Steins M, Ready N,et al.Phase III, randomized trial (CheckMate 057) of nivolumab(NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).J Clin Oncol 2015;33:LBA109.

    49.Antonia SJ, Brahmer JR, Gettinger S, Chow LQ, Juergens R,Shepherd FA, et al.Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy(PT-DC) in advanced non-small cell lung cancer (NSCLC).Int J Radiat Oncol Biol Phys 2014;90:S2.

    50.Gettinger S, Chow LQ, Borghaei H, Shen Y, Harbison C, Chen AC, et al.Safety and response with nivolumab (Anti-PD-1;BMS-936558, ONO-4538) plus erlotinib in patients (Pts) with epidermal growth factor receptor mutant (EGFR MT) advanced non-small cell lung cancer (NSCLC).Int J Radiat Oncol Biol Phys 2014;90:S34-S35.

    51.Rizvi NA, Chow LQ, Borghaei H, Shen Y, Harbison C, Alaparthy S, et al.Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC.J Clin Oncol 2014;32:abstr 8022.

    52.Antonia SJ, Gettinger SN, Chow LQ, Juergens RA, Borghaei H,Shen Y, et al.Nivolumab (anti-PD-1; BMS-936558, ONO-4538)and ipilimumab in first-line NSCLC: Interim phase I results.J Clin Oncol 2014;32:abstr 8023.

    53.Antonia SJ, Bendell JC, Taylor MH, Calvo E, Jaeger D, De Braud FG, et al.Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer(SCLC): CA209-032.J Clin Oncol 2015;33:abstr 7503.

    54.Garon EB, Balmanoukian A, Hamid O, Hui R, Gandhi L, Leighi N, et al.Preliminary safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer(NSCLC).Annual Congress of the American Society of Clinical Oncology (ASCO) 2014.

    55.Rizvi NA, Garon EB, Patnaik A, Gandhi L, Leighl NB,Balmanoukian AS, et al.Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer(NSCLC).J Clin Oncol 2014;32:abstr 8007.

    56.Ott PA, Maria Elez-Fernandez ME, Hiret S, Kim DW, Moss RA,Winser T, et al.Pembrolizumab (MK-3475) in patients (pts)with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028.J Clin Oncol 2015;33:abstr 7502.

    57.Patnaik A, Socinski MA, Gubens MA, Gandhi L, Stevenson J,Bachman RD, et al.Phase 1 study of pembrolizumab (pembro;MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.J Clin Oncol 2015;33:abstr 8011.

    58.Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P,et al.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N Engl J Med 2012;366:2455-2465.

    59.Segal NH, Antonia SJ, Brahmer JR, Maio M, Blake-Haskins A, Li X, et al.Preliminary data from a multi-arm expansion study of MEDI4736,an anti-PD-L1 antibody.J Clin Oncol 2014;32:abstr 3002^.

    60.Khleif S, Lutzky J, Segal N, Antonia S, Blake-Haskins A, Stewart R, et al.MEDI4736, an anti-PD-L1 antibody with modified Fc domain: Preclinical evaluation and early clinical results from a phase 1 study in patients with advanced solid tumors.Eur J Cancer 2013;49:abstr 802.

    61.Soria JC, Cruz C, Bahleda R, Delord JP, Horn L, Herbst RS, et al.Clinical activity, safety, and biomarkers of a PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1).Eur J Cancer 2013;49:abstr 3408.

    62.Spira AI, Park K, Mazières J, Vansteenkiste JF, Rittmeyer A,Ballinger M, et al.Efficacy, safety and predictive biomarker results from a randomized phase II study comparing atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR).J Clin Oncol 2015;33:abstr 8010.

    63.Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al.Overall survival and long-term safety of nivolumab(Anti-programmed death 1 antibody, BMS-936558, ONO-4538)in patients with previously treated advanced non-small-cell lung cancer.J Clin Oncol 2015;33:2004-2012.

    64.Garon EB, Gandhi L, Rizvi N, Hui R, Balmanoukian AS, Patnaik A,et al.Antitumor activity of pembrolizumab (pembro; MK-3475)and correlation with programmed death ligand 1 (PD-l1) expression in a pooled analysis of patients (pts) with advanced non–small cell lung carcinoma (NSCLC).Ann Oncol 2014;25:v1-v41.

    65.Lutzky J, Antonia SJ, Blake-Haskins A, Li X, Robbins PB,Shalabi AM, et al.A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors.J Clin Oncol 2014;32:abstr 3001^.

    66.Spigel DR, Gettinger SN, Horn L, Herbst RS, Gandhi L, Gordon MS, et al.Clinical activity, safety, and biomarkers of MPDL3280A,an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).J Clin Oncol 2013;31:abstr 8008.

    67.Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS,et al.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.Nature 2014;515:563-567.

    68.Gandhi L, Balmanoukian A, Hui R, Hamid O, Rizvi NA, Leighl N, et al.Abstract CT105: MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): Antitumor activity and association with tumor PD-L1 expression.Cancer Res 2014;74:CT105.

    69.Gettinger SN, Shepherd FA, Antonia SJ, Brahmer JR, Quan Man Chow L, Juergens RA, et al.First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety,efficacy, and correlation of outcomes with PD-L1 status.J Clin Oncol 2014;32:abstr 8024.

    70.Brahmer JR, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al.Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC):Survival and clinical activity by subgroup analysis.J Clin Oncol 2014;32:abstr 8112^.

    71.Brahmer JR, Rizvi NA, Lutzky J, Khleif S, Blake-Haskins A,Li X, et al.Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC.J Clin Oncol 2014;32:abstr 8021^.

    72.Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al.Pembrolizumab for the treatment of non-small-cell lung cancer.N Engl J Med 2015;372:2018-2028.

    73.Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al.Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.Clin Cancer Res 2014;20:5064-5074.

    74.Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ,Robert L, et al.PD-1 blockade induces responses by inhibiting adaptive immune resistance.Nature 2014;515:568-571.

    75.Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK.Nonsmall-cell lung cancers: a heterogeneous set of diseases.Nat Rev Cancer 2014;14:535-546.

    76.Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, et al.BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.Clin Cancer Res 2013;19:1225-1231.

    77.Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH,Christensen CL, et al.Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.Cancer Discov 2013;3:1355-1363.

    78.D’Incecco A, Andreozzi M, Ludovini V, Rossi E, Landi L, Minuti G, et al.PD-L1 and PD-1 expression in molecularly selected non-small-cell lung cancer (NSCLC) patients.J Thorac Oncol 2014;9:S7-S52.

    79.Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al.Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.N Engl J Med 2011;364:2517-2526.

    80.Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al.Immunologic correlates of the abscopal effect in a patient with melanoma.N Engl J Med 2012;366:925-931.

    81.Kong YC, Flynn JC.Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and Anti-PD-1.Front Immunol 2014;5:206.

    82.Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al.Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.N Engl J Med 2015;373:23-34.

    83.McDermott D, Haanen J, Chen TT, Lorigan P, O’Day S.Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial(MDX010-20).Ann Oncol 2013;24:2694-2698.

    84.Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R, et al.Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.Cancer Immunol Immunother 2012;61:41-48.

    85.Yousaf N, Davidson M, Goode E, Thomas C, Hung R, Gore M,et al.The cost of ipilimumab toxicity: a single-centre analysis.Melanoma Res 2015;25:259-264.

    86.McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD,Smith DC, et al.Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab.J Clin Oncol 2015;33:2013-2020.

    87.Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al.Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.Cancer Res 2012;72:917-927.

    88.Benson DM Jr, Cohen AD, Jagannath S, Munshi NC, Spitzer G,Hofmeister CC, et al.A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma.Clin Cancer Res 2015;21:4055-4061.

    89.Clouthier DL, Zhou AC, Watts TH.Anti-GITR agonist therapy intrinsically enhances CD8 T cell responses to chronic lymphocytic choriomeningitis virus (LCMV), thereby circumventing LCMV-induced downregulation of costimulatory GITR ligand on APC.J Immunol 2014;193:5033-5043.

    90.Kobayashi T, Doff BL, Rearden RC, Leggatt GR, Mattarollo SR.NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma.Oncoimmunology 2015;4:e990793.

    91.Lei F, Song J, Haque R, Haque M, Xiong X, Fang D, et al.Regulation of A1 by OX40 contributes to CD8(+) T cell survival and anti-tumor activity.PLoS One 2013;8:e70635.

    92.Batchu RB, Gruzdyn O, Potti RB, Weaver DW, Gruber SA.MAGE-A3 with cell-penetrating domain as an efficient therapeutic cancer vaccine.JAMA Surg 2014;149:451-457.

    93.Ohgami A, Tsuda T, Osaki T, Mitsudomi T, Morimoto Y,Higashi T, et al.MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence.AnnThorac Surg 1999;67:810-814.

    94.Mitchell P, Thatcher N, Socinski MA, Wasilewska-Tesluk E, Horwood K, Szczesna A, et al.Tecemotide in unresectable stage III non-smallcell lung cancer in the phase III START study: updated overall survival and biomarker analyses.Ann Oncol 2015;26:1134-1142.

    95.Rodriguez PC, Neninger E, Garcia B, Popa X, Viada C, Luaces P, et al.Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an epidermal growth factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients.J Immune Based Ther Vaccines 2011;9:7.

    96.Brunsvig PF, Kyte JA, Kersten C, Sundstrom S, Moller M, Nyakas M,et al.Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.Clin Cancer Res 2011;17:6847-6857.

    97.Kakimi K, Isobe M, Uenaka A, Wada H, Sato E, Doki Y, et al.A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.Int J Cancer 2011;129:2836-2846.

    98.Giaccone G, Bazhenova L, Nemunaitis J, et al.A phase III study of belagenpumatucel-L therapeutic tumor cell vaccine for non-small cell lung cancer.2013 Europen Cancer Congress 2013:Abs LBA2.

    99.Morris JC, Rossi GR, Harold N, Tennant L, Ramsey WJ, Vahanian N, et al.Potential chemo-sensitization effect of tergenpumatucel-L immunotherapy in treated ptients with advanced non-small cell lung cancer 8NSCLC).J Clin Oncol 2013;31:abstr 8094.

    100.Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen SK, Bjoern J, et al.Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.Clin Cancer Res 2014;20:221-232.

    视频在线观看一区二区三区| 久久精品人人爽人人爽视色| 久久av网站| 久久久久久久久久人人人人人人| 狠狠婷婷综合久久久久久88av| 久久久亚洲精品成人影院| 亚洲熟女精品中文字幕| 色婷婷av一区二区三区视频| 美女国产视频在线观看| 搡老乐熟女国产| av电影中文网址| 99久国产av精品国产电影| 精品一区二区三区视频在线| 国产爽快片一区二区三区| 狠狠精品人妻久久久久久综合| 乱码一卡2卡4卡精品| 高清视频免费观看一区二区| 熟女电影av网| 男女啪啪激烈高潮av片| 一区二区av电影网| 一级毛片 在线播放| 精品久久久久久久久av| 日本av手机在线免费观看| av电影中文网址| 国产在线一区二区三区精| 欧美日本中文国产一区发布| 欧美精品一区二区免费开放| 久久久久久久精品精品| 亚洲成人一二三区av| 久久久欧美国产精品| 国产成人精品无人区| 亚洲精品乱久久久久久| 欧美日韩av久久| 天天影视国产精品| 欧美精品一区二区大全| 午夜激情久久久久久久| 欧美xxxx性猛交bbbb| 男女无遮挡免费网站观看| 国产精品久久久久久久电影| 亚洲国产欧美在线一区| 狂野欧美激情性bbbbbb| 久久av网站| av在线观看视频网站免费| 成人影院久久| 91精品国产九色| 亚洲人成网站在线观看播放| 99国产精品免费福利视频| 你懂的网址亚洲精品在线观看| 全区人妻精品视频| 成人手机av| 国产欧美另类精品又又久久亚洲欧美| 高清av免费在线| 一边亲一边摸免费视频| 中文字幕最新亚洲高清| 免费观看无遮挡的男女| 婷婷色综合www| 熟女人妻精品中文字幕| 蜜桃国产av成人99| 丝瓜视频免费看黄片| 男人添女人高潮全过程视频| 午夜视频国产福利| 九草在线视频观看| 国产精品久久久久久久电影| 91aial.com中文字幕在线观看| 丰满迷人的少妇在线观看| 国产日韩欧美视频二区| 国产在线免费精品| 国产成人91sexporn| 亚洲婷婷狠狠爱综合网| 国产日韩欧美在线精品| 日韩av在线免费看完整版不卡| 国产精品免费大片| 爱豆传媒免费全集在线观看| 2021少妇久久久久久久久久久| 在线观看人妻少妇| 中文字幕人妻丝袜制服| 国产精品三级大全| 婷婷色av中文字幕| 人人妻人人澡人人爽人人夜夜| 视频区图区小说| 国产免费一区二区三区四区乱码| 夜夜爽夜夜爽视频| 只有这里有精品99| 国产精品久久久久久av不卡| 日日啪夜夜爽| 午夜福利网站1000一区二区三区| 丰满迷人的少妇在线观看| 欧美3d第一页| 老司机影院毛片| 亚洲av.av天堂| av电影中文网址| 国产成人精品一,二区| 亚洲欧美精品自产自拍| 18禁在线播放成人免费| 欧美成人午夜免费资源| 熟女电影av网| 久久ye,这里只有精品| 99热这里只有是精品在线观看| 欧美激情国产日韩精品一区| 日韩伦理黄色片| 国精品久久久久久国模美| 99热这里只有精品一区| 制服丝袜香蕉在线| 在线观看国产h片| 欧美丝袜亚洲另类| 精品酒店卫生间| 午夜日本视频在线| 一区二区av电影网| 久久久国产一区二区| 卡戴珊不雅视频在线播放| 建设人人有责人人尽责人人享有的| 能在线免费看毛片的网站| 亚洲国产精品成人久久小说| 99热6这里只有精品| 久久精品国产鲁丝片午夜精品| 亚洲无线观看免费| 永久网站在线| 精品国产一区二区久久| 91久久精品国产一区二区三区| 国模一区二区三区四区视频| 久久久精品区二区三区| 黄色欧美视频在线观看| 免费大片黄手机在线观看| 久久久久久久久久久久大奶| 一本色道久久久久久精品综合| 亚洲四区av| av视频免费观看在线观看| 这个男人来自地球电影免费观看 | 久久久欧美国产精品| 欧美日韩在线观看h| 黄色毛片三级朝国网站| 日韩视频在线欧美| 欧美人与性动交α欧美精品济南到 | 乱人伦中国视频| 高清午夜精品一区二区三区| 精品一区在线观看国产| 国产欧美日韩一区二区三区在线 | 水蜜桃什么品种好| 日韩,欧美,国产一区二区三区| 人人妻人人澡人人看| 亚洲精品国产av成人精品| 美女中出高潮动态图| 午夜日本视频在线| 卡戴珊不雅视频在线播放| av在线老鸭窝| 国产黄频视频在线观看| 丰满少妇做爰视频| 在线播放无遮挡| 最新中文字幕久久久久| 男人爽女人下面视频在线观看| 少妇被粗大的猛进出69影院 | 亚洲怡红院男人天堂| 国语对白做爰xxxⅹ性视频网站| 国产免费又黄又爽又色| 3wmmmm亚洲av在线观看| 中文字幕精品免费在线观看视频 | 亚洲激情五月婷婷啪啪| 美女福利国产在线| 热99久久久久精品小说推荐| 亚洲国产精品专区欧美| 国产老妇伦熟女老妇高清| 国产伦理片在线播放av一区| 亚洲怡红院男人天堂| 五月天丁香电影| 国产精品人妻久久久久久| 哪个播放器可以免费观看大片| 大片免费播放器 马上看| 日韩视频在线欧美| 国产国语露脸激情在线看| 2021少妇久久久久久久久久久| 97超碰精品成人国产| 日韩中字成人| 曰老女人黄片| 国产精品.久久久| 大码成人一级视频| 久久久久久久大尺度免费视频| 狠狠婷婷综合久久久久久88av| 97在线视频观看| 久热久热在线精品观看| 22中文网久久字幕| 美女内射精品一级片tv| 国产伦理片在线播放av一区| 精品午夜福利在线看| 丰满饥渴人妻一区二区三| 亚洲av二区三区四区| 国产成人精品婷婷| 久久久久久久大尺度免费视频| av.在线天堂| 9色porny在线观看| 精品久久久噜噜| 91国产中文字幕| 一级毛片我不卡| 国产av一区二区精品久久| 欧美日韩精品成人综合77777| 美女cb高潮喷水在线观看| 国产伦理片在线播放av一区| 中文精品一卡2卡3卡4更新| a级毛色黄片| 久久久国产精品麻豆| 久久久久久伊人网av| videossex国产| 成年av动漫网址| 亚洲成人av在线免费| 亚洲国产av影院在线观看| 丰满乱子伦码专区| 精品卡一卡二卡四卡免费| 久久韩国三级中文字幕| 欧美丝袜亚洲另类| 欧美激情国产日韩精品一区| 国产黄频视频在线观看| 免费大片18禁| 国产精品国产三级国产专区5o| 国产精品不卡视频一区二区| 亚洲精品自拍成人| av一本久久久久| 少妇 在线观看| 亚洲精华国产精华液的使用体验| 婷婷色麻豆天堂久久| 国产精品女同一区二区软件| 欧美亚洲日本最大视频资源| 日韩,欧美,国产一区二区三区| 最新中文字幕久久久久| 亚洲成人手机| 欧美亚洲日本最大视频资源| 亚洲激情五月婷婷啪啪| 日本欧美国产在线视频| 亚洲成色77777| 多毛熟女@视频| 亚洲不卡免费看| 国产黄色免费在线视频| 国产精品熟女久久久久浪| 国产在线视频一区二区| 一本色道久久久久久精品综合| 亚洲国产色片| a级片在线免费高清观看视频| 老女人水多毛片| 国产精品蜜桃在线观看| 女性生殖器流出的白浆| 一区二区av电影网| 99久久精品国产国产毛片| 免费看不卡的av| 国产精品秋霞免费鲁丝片| 色婷婷久久久亚洲欧美| 蜜桃久久精品国产亚洲av| 亚洲中文av在线| 99久久中文字幕三级久久日本| 9色porny在线观看| 飞空精品影院首页| 成人免费观看视频高清| 免费播放大片免费观看视频在线观看| 观看美女的网站| 欧美日韩亚洲高清精品| 人妻制服诱惑在线中文字幕| 一区在线观看完整版| 亚洲精品久久午夜乱码| 特大巨黑吊av在线直播| 九草在线视频观看| 日本vs欧美在线观看视频| 国产免费一区二区三区四区乱码| 久久久国产欧美日韩av| 亚洲国产精品一区二区三区在线| xxx大片免费视频| 亚洲欧美一区二区三区国产| 国产精品国产av在线观看| 国产精品秋霞免费鲁丝片| 建设人人有责人人尽责人人享有的| 欧美xxⅹ黑人| 能在线免费看毛片的网站| 91精品三级在线观看| √禁漫天堂资源中文www| av黄色大香蕉| 九九久久精品国产亚洲av麻豆| 日本黄色片子视频| 视频在线观看一区二区三区| 国产成人aa在线观看| 国产熟女欧美一区二区| 毛片一级片免费看久久久久| 国产成人一区二区在线| 伦理电影免费视频| 日韩精品免费视频一区二区三区 | 男人操女人黄网站| 亚洲精品成人av观看孕妇| 久久人妻熟女aⅴ| 国产成人免费无遮挡视频| 亚洲丝袜综合中文字幕| 777米奇影视久久| 熟妇人妻不卡中文字幕| 免费观看a级毛片全部| 国产精品99久久99久久久不卡 | 曰老女人黄片| 国产免费一级a男人的天堂| videossex国产| 亚洲,欧美,日韩| 一级毛片电影观看| 黄色欧美视频在线观看| 免费不卡的大黄色大毛片视频在线观看| 久久久久久久国产电影| 亚洲天堂av无毛| 最近2019中文字幕mv第一页| 交换朋友夫妻互换小说| 亚洲国产精品成人久久小说| 国产免费一级a男人的天堂| 日韩欧美精品免费久久| 久久久久久久久久人人人人人人| 精品卡一卡二卡四卡免费| 免费看光身美女| 国产片内射在线| 国产淫语在线视频| 亚洲国产欧美在线一区| 日本欧美视频一区| 国产男人的电影天堂91| 国产色婷婷99| 亚洲av福利一区| 91成人精品电影| 看非洲黑人一级黄片| 日本黄色片子视频| 国产午夜精品久久久久久一区二区三区| 曰老女人黄片| 精品人妻偷拍中文字幕| 亚洲欧美中文字幕日韩二区| 亚洲欧美一区二区三区黑人 | 久久综合国产亚洲精品| 日韩在线高清观看一区二区三区| 狂野欧美激情性xxxx在线观看| 青春草视频在线免费观看| 美女国产视频在线观看| 精品亚洲成a人片在线观看| 成人国产麻豆网| 欧美成人精品欧美一级黄| 蜜臀久久99精品久久宅男| 美女国产高潮福利片在线看| 永久免费av网站大全| 国内精品宾馆在线| 日本黄大片高清| 一本大道久久a久久精品| 亚洲av二区三区四区| 日日爽夜夜爽网站| 国产精品.久久久| 国产高清有码在线观看视频| 亚洲精品美女久久av网站| 青春草亚洲视频在线观看| 80岁老熟妇乱子伦牲交| 一级毛片电影观看| 亚洲精华国产精华液的使用体验| 国产日韩一区二区三区精品不卡 | 五月玫瑰六月丁香| 亚洲图色成人| 日韩一本色道免费dvd| 国产视频首页在线观看| 亚洲精品国产av蜜桃| 亚洲精品亚洲一区二区| 久久精品久久精品一区二区三区| 国产欧美亚洲国产| 国产精品久久久久久av不卡| 色网站视频免费| 午夜91福利影院| 亚洲经典国产精华液单| 精品久久久精品久久久| 99视频精品全部免费 在线| 卡戴珊不雅视频在线播放| 国产成人精品福利久久| 18禁在线无遮挡免费观看视频| 国产免费现黄频在线看| 18禁在线无遮挡免费观看视频| 国产免费现黄频在线看| 成人免费观看视频高清| 91久久精品国产一区二区成人| 高清视频免费观看一区二区| 国产高清有码在线观看视频| 久久久国产精品麻豆| 久久韩国三级中文字幕| 色网站视频免费| 亚洲国产最新在线播放| 日本免费在线观看一区| 大香蕉97超碰在线| 三级国产精品欧美在线观看| 曰老女人黄片| 这个男人来自地球电影免费观看 | 国产 一区精品| 啦啦啦啦在线视频资源| 亚洲天堂av无毛| 欧美 日韩 精品 国产| 精品久久久久久久久亚洲| 亚洲国产欧美日韩在线播放| 国产欧美日韩综合在线一区二区| 国产精品蜜桃在线观看| 日韩制服骚丝袜av| 国产一区有黄有色的免费视频| 五月玫瑰六月丁香| 一区二区日韩欧美中文字幕 | 天美传媒精品一区二区| 少妇高潮的动态图| 嫩草影院入口| 人体艺术视频欧美日本| 免费日韩欧美在线观看| 日韩av不卡免费在线播放| 99热6这里只有精品| 免费高清在线观看视频在线观看| 欧美3d第一页| 亚洲欧美成人综合另类久久久| 欧美成人午夜免费资源| 免费不卡的大黄色大毛片视频在线观看| 亚洲av成人精品一区久久| 97超视频在线观看视频| 99热这里只有精品一区| 男女免费视频国产| 国产亚洲午夜精品一区二区久久| av免费在线看不卡| 99热全是精品| 人体艺术视频欧美日本| 欧美性感艳星| 另类亚洲欧美激情| 日韩大片免费观看网站| 国产在线一区二区三区精| 成人国产麻豆网| 亚洲av不卡在线观看| 国产黄频视频在线观看| 国产精品一区www在线观看| 岛国毛片在线播放| 国产片内射在线| 精品99又大又爽又粗少妇毛片| 大话2 男鬼变身卡| 免费大片18禁| h视频一区二区三区| 日韩中字成人| 国产成人aa在线观看| 亚洲经典国产精华液单| 亚洲情色 制服丝袜| 男人添女人高潮全过程视频| www.色视频.com| 午夜精品国产一区二区电影| 国产成人精品久久久久久| 99九九在线精品视频| 高清视频免费观看一区二区| 中文字幕最新亚洲高清| 26uuu在线亚洲综合色| 国产片特级美女逼逼视频| 欧美激情 高清一区二区三区| 亚洲伊人久久精品综合| 一本一本综合久久| 精品人妻熟女毛片av久久网站| 日日撸夜夜添| 51国产日韩欧美| 日本黄大片高清| 毛片一级片免费看久久久久| 国产精品人妻久久久久久| 黑人高潮一二区| 国产爽快片一区二区三区| 中文欧美无线码| 麻豆乱淫一区二区| 亚洲国产精品一区二区三区在线| 精品少妇久久久久久888优播| 天天影视国产精品| 美女国产视频在线观看| 热re99久久精品国产66热6| 亚洲精品aⅴ在线观看| 嫩草影院入口| 一个人看视频在线观看www免费| 免费av中文字幕在线| 黄色欧美视频在线观看| 99久久中文字幕三级久久日本| 自线自在国产av| 亚洲天堂av无毛| 久久99热6这里只有精品| 黄色毛片三级朝国网站| 久久久久久久久久久丰满| 男女边摸边吃奶| 亚洲欧美清纯卡通| 看十八女毛片水多多多| 一级二级三级毛片免费看| 亚洲精品久久成人aⅴ小说 | 亚洲精品色激情综合| 成年av动漫网址| 亚洲美女黄色视频免费看| 一边摸一边做爽爽视频免费| 22中文网久久字幕| 男人爽女人下面视频在线观看| 制服丝袜香蕉在线| 亚洲综合精品二区| 欧美日韩综合久久久久久| 精品少妇内射三级| 少妇高潮的动态图| 最近中文字幕高清免费大全6| 色5月婷婷丁香| 黑人欧美特级aaaaaa片| 亚洲无线观看免费| 国模一区二区三区四区视频| 欧美xxⅹ黑人| 亚洲国产色片| 母亲3免费完整高清在线观看 | 国产精品免费大片| 熟妇人妻不卡中文字幕| 26uuu在线亚洲综合色| 国产精品一二三区在线看| 久久久午夜欧美精品| 久久久久精品性色| 亚洲精品aⅴ在线观看| 曰老女人黄片| 交换朋友夫妻互换小说| 高清欧美精品videossex| 久久人妻熟女aⅴ| 久久久久网色| 成人亚洲欧美一区二区av| 国产片内射在线| 日韩欧美一区视频在线观看| 成人午夜精彩视频在线观看| 久久人人爽人人爽人人片va| 亚洲三级黄色毛片| 又粗又硬又长又爽又黄的视频| 亚洲第一av免费看| 777米奇影视久久| 国产淫语在线视频| 午夜久久久在线观看| 精品人妻在线不人妻| 亚洲精品国产色婷婷电影| 国产又色又爽无遮挡免| 日韩强制内射视频| 国产精品国产av在线观看| 伦理电影免费视频| 国产av一区二区精品久久| 一边亲一边摸免费视频| 亚洲丝袜综合中文字幕| 美女xxoo啪啪120秒动态图| 亚洲av二区三区四区| 国产精品99久久99久久久不卡 | 亚洲精品乱码久久久v下载方式| 一边亲一边摸免费视频| 黄色一级大片看看| 女性被躁到高潮视频| 男人操女人黄网站| 亚洲av成人精品一区久久| 国产综合精华液| 大陆偷拍与自拍| 韩国av在线不卡| 亚洲综合色惰| 午夜福利,免费看| 婷婷色综合www| 国产午夜精品久久久久久一区二区三区| 精品亚洲乱码少妇综合久久| 一级毛片电影观看| 国产高清不卡午夜福利| 麻豆乱淫一区二区| 成人国产av品久久久| 一本色道久久久久久精品综合| 国产伦理片在线播放av一区| 高清欧美精品videossex| 91aial.com中文字幕在线观看| tube8黄色片| 99九九线精品视频在线观看视频| 在线天堂最新版资源| 妹子高潮喷水视频| av又黄又爽大尺度在线免费看| 不卡视频在线观看欧美| 亚洲欧美中文字幕日韩二区| 成人国产麻豆网| 久久毛片免费看一区二区三区| 好男人视频免费观看在线| freevideosex欧美| 老女人水多毛片| 国产成人av激情在线播放 | 男男h啪啪无遮挡| 亚洲一区二区三区欧美精品| 涩涩av久久男人的天堂| 在线观看美女被高潮喷水网站| 国产成人精品久久久久久| 特大巨黑吊av在线直播| 亚洲欧洲日产国产| 老司机影院毛片| 国产精品一二三区在线看| 日韩伦理黄色片| 国产亚洲av片在线观看秒播厂| 国产成人精品婷婷| 久久久久久久亚洲中文字幕| 免费高清在线观看日韩| av电影中文网址| 欧美精品一区二区大全| 欧美 亚洲 国产 日韩一| 免费观看在线日韩| 秋霞在线观看毛片| 亚洲天堂av无毛| av黄色大香蕉| 精品久久蜜臀av无| 亚洲美女搞黄在线观看| 成人国产av品久久久| 91久久精品国产一区二区成人| 制服丝袜香蕉在线| 国产亚洲一区二区精品| 精品久久久久久久久亚洲| 纯流量卡能插随身wifi吗| 成人国语在线视频| 秋霞伦理黄片| 国产日韩一区二区三区精品不卡 | 又大又黄又爽视频免费| 久久精品国产亚洲av天美| 一本色道久久久久久精品综合| 精品一品国产午夜福利视频| 亚洲国产精品一区三区| 黄色配什么色好看| 成人无遮挡网站| 国产精品 国内视频| 香蕉精品网在线| 我的女老师完整版在线观看| 日韩欧美一区视频在线观看| 黄色怎么调成土黄色| 人体艺术视频欧美日本| av女优亚洲男人天堂| 免费人妻精品一区二区三区视频| 国产爽快片一区二区三区| 在线观看三级黄色| 欧美老熟妇乱子伦牲交| 中文字幕av电影在线播放| 制服丝袜香蕉在线| 天堂俺去俺来也www色官网| 又大又黄又爽视频免费| videos熟女内射|